LIGAND PHARMACEUTICALS INC (LGND)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, LIGAND PHARMACEUTICALS INC reported revenue of $268.09M, up 60.4% from the prior year. The company was profitable, with a net margin of 46.4%. It held $1.56B in total assets against $543.42M in total liabilities.
Key ratios (FY2025)
15.3%
Operating margin
46.4%
Net margin
12.2%
Return on equity
+60.4%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $268.09M | $167.13M | $131.31M | $196.25M | $241.54M | $163.56M | $120.28M | $251.45M | $141.10M | $108.97M |
| Cost of Revenue | — | — | — | — | — | — | — | $6.34M | $5.37M | $5.57M |
| Operating Income | $41.00M | -$22.61M | $11.94M | $3.04M | $103.85M | $37.50M | $807.08M | $163.73M | $68.08M | $43.88M |
| Net Income | $124.45M | -$4.03M | $52.15M | -$33.36M | $57.14M | -$2.98M | $629.30M | $143.32M | $12.56M | -$1.64M |
| EPS (Diluted) | $6.13 | $-0.22 | $2.94 | $-1.98 | $3.31 | $-0.18 | $31.85 | $5.96 | $0.53 | $-0.08 |
| Total Assets | $1.56B | $941.77M | $787.22M | $762.67M | $1.30B | $1.36B | $1.49B | $1.26B | $671.02M | $601.59M |
| Total Liabilities | $543.42M | $111.33M | $86.30M | $165.18M | $476.43M | $652.76M | $727.68M | $699.89M | $252.37M | $230.73M |
| Shareholders' Equity | $1.02B | $830.44M | $700.91M | $597.49M | $821.16M | $709.52M | $767.23M | $560.91M | $399.79M | $341.29M |
| Cash & Equivalents | $174.93M | $72.31M | $22.95M | $45.01M | $19.52M | $47.62M | $71.54M | $117.16M | $20.62M | $18.75M |
| Operating Cash Flow | $49.36M | $97.05M | $49.58M | $137.85M | $78.80M | $54.59M | -$29.34M | $194.06M | $88.57M | $60.73M |
| Capital Expenditures | $452.0K | $1.82M | $3.52M | $17.92M | $8.76M | $4.46M | $2.55M | $887.0K | $2.16M | $1.85M |
| Shares Outstanding | 20.29M | 18.29M | 17.76M | 16.87M | 17.25M | 16.82M | 19.76M | 24.07M | 23.48M | 20.83M |